Spyre Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Spyre Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,891% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +993%In 3 years sales changed by -100% while total assets changed by +993%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Spyre Therapeutics, Inc. made a loss over the last year. Spyre Therapeutics, Inc. owes $0.06 for every $1 it owns. Spyre Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSpyre Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
7.84The share price is 7.84 times Spyre Therapeutics, Inc.'s book value per share, higher than 82% of Healthcare companies in United States.
Market cap
$8.6 BThe total market value of all of Spyre Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.1 BWhat Spyre Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.78Net worth divided by the number of shares. The share price of $92.33 is 7.8 times this, which is the P/B above.
Return on equity (ROE)
-23.0%Spyre Therapeutics, Inc. lost 23.0% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.06×Spyre Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Dividend yield
NoneSpyre Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossSpyre Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Spyre Therapeutics, Inc.: $8.6 B ÷ $1.1 B (30 Jun 2026) = 7.8.
What is Spyre Therapeutics, Inc.'s return on equity?
Spyre Therapeutics, Inc. lost 23.0% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does Spyre Therapeutics, Inc. owe compared with what it owns?
Spyre Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Does Spyre Therapeutics, Inc. pay a dividend?
No. Spyre Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.